Somatic Mutations and Clonal Hematopoiesis
Unexpected Potential New Drivers of Age-Related Cardiovascular Disease

José J. Fuster, Kenneth Walsh

Abstract: Increasing evidence shows that conventional cardiovascular risk factors are incompletely predictive of cardiovascular disease, particularly in elderly individuals, suggesting that there may still be unidentified causal risk factors. Although the accumulation of somatic DNA mutations is a hallmark of aging, its relevance in cardiovascular disease or other age-related conditions has been, with the exception of cancer, largely unexplored. Here, we review recent clinical and preclinical studies that have identified acquired mutations in hematopoietic stem cells and subsequent clonal hematopoiesis as a new cardiovascular risk factor and a potential major driver of atherosclerosis. Understanding the mechanisms underlying the connection between somatic mutation-driven clonal hematopoiesis and cardiovascular disease will be highly relevant in the context of personalized medicine, as it may provide key information for the design of diagnostic, preventive, or therapeutic strategies tailored to the effects of specific somatic mutations. (Circ Res. 2018;122:523-532. DOI: 10.1161/CIRCRESAHA.117.312115.)

Key Words: aging ■ atherosclerosis ■ cardiovascular disease ■ CHIP ■ inflammation ■ risk factors

Aging and Cardiovascular Disease, an Incompletely Understood Connection
Cardiovascular/cerebrovascular disease (CVD) is the leading cause of morbidity and mortality in both industrialized and low-to middle-income countries, particularly in the elderly population. Furthermore, this situation is expected to worsen as the world population is aging and CVD incidence steeply increases with age, accounting for >40% of total deaths and >85% of chronic disease deaths in those older than 70 years.1 Although epidemiological studies clearly show that advanced age is the most important risk factor for CVD, we have an incomplete understanding of how it promotes disease progression, in particular in the context of atherosclerosis. Although the effect of aging on atherosclerotic CVD reflects to a great extent the cumulative exposure to many traditional risk factors (eg, hypercholesterolemia, diabetes mellitus, hypertension, smoking),2 clinical evidence suggests that additional, still unidentified age-related factors may contribute to atherosclerosis development. Indeed, age remains an independent risk factor for CVD even after statistical adjustment for traditional risk factors,3,4 and most CVD events occur in elderly individuals who are at low or intermediate risk based on traditional risk factors. For example, an international study that included >120000 athero- sclerotic CVD patients revealed that ≈65% of patients older than 65 years old had either none or just one conventional cardiovascular risk factor.5 Consistent with this observation, imaging studies show that most individuals at low cardiovascular risk based on conventional risk algorithms exhibit substantial subclinical atherosclerosis.6-9 In addition, emerging evidence suggests that the effects of some conventional risk factors on cardiovascular risk differ between young and elderly individuals. For example, the impact of hypercholesterolemia on cardiovascular risk has been shown to gradually decrease with aging in several studies,10-12 suggesting the existence of alternative nonconventional risk factors that contribute to the pathogenesis of atherosclerotic CVD in the elderly population. Consistent with these results, recent clinical trials of treatments with high-intensity statin regimens or new cholesterol-lowering drugs (eg, PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) show that, despite massive reductions in blood cholesterol levels, atherosclerotic plaques progress in a significant proportion of individuals13,14 and a substantial level of residual cardiovascular risk remains.15,16 Therefore, although the major contribution to atherosclerosis of the cumulative exposure to conventional risk factors—particularly hypercholesterolemia—is undeniable,17 these aforementioned studies lead inevitably to the question: what else is driving atherosclerotic CVD in the elderly? Emerging evidence from human and mouse studies suggests that the acquisition of somatic mutations in hematopoietic cells may be part of the answer to this question.

Somatic Mutations in the Hematopoietic System and Atherosclerotic CVD: Evidence From Human Studies
Over the past 2 decades, research on the impact of human genet- ics on CVD has focused mostly on genetic variation transmitted through the germ line.18,19 Although these studies have unveiled a contribution of many inherited variants to CVD, recent evidence suggests that noninherited, acquired mutations that affect somatic cells may also be important players in CVD and...
related HSPC clones.40 Peripheral blood cells from a 115-year-old woman revealed that clonal hematopoiesis based on the results of X chromosome cells. Early studies documented the occurrence of age-related lar progeny, in the blood and other tissues infiltrated by blood tant HSPC in the hematopoietic system and, through its cellu-
advantage eventually leads to the clonal expansion of the mu-
confers a competitive advantage to the cell, which leads to the progressive expansion of the mutant clone. Consequently, indi-
become a mosaic of cells with different genotypes over time.21,23,24 Accumulating evidence reveals that this somatic ge-
confers a competitive advantage to the cell, which leads to the progression of the mutant clone. Consequently, indi-
mutations have no effect on cellular function or in some cases
mutations have no or little phenotypic consequences, as most
mutations have no effect on cellular function or in some cases
occurs randomly, beginning in prenatal development.20–22 In most
cases, they have no or little phenotypic consequences, as most
mutations have no effect on cellular function or in some cases
are toxic or even lethal to the mutant cell, leading to its quick
disappearance. However, in a few instances, a somatic mutation
confers a competitive advantage to the cell, which leads to the
progressive expansion of the mutant clone. Consequently, indi-
clonal hematopoiesis occur in 3 genes (DNA methyltransferase
3α [DNMT3A], tet methylcytosine dioxygenase 2 [TET2], and
additional sex combs like 1 [ASXL1]) that encode for epigen-
etic regulators that have been implicated in the control of he-
maferesis.45–55 It can be estimated that at least 10% to 20% of
individuals older than 65 years old exhibit a significant fraction
of white blood cells (eg, >4%) that harbor somatic mutations
in these or other known driver genes.34–36 Furthermore, highly
sensitive sequencing techniques that allow the detection of mu-
tations in a smaller percentage of blood cells suggest that low
levels of clonal hematopoiesis may be even more prevalent,
trending toward inevitability in the very elderly.31,33,37 Despite
these observations, the relevance of clonal hematopoiesis in
the context of age-associated disorders other than cancer has
potentially other age-related disorders. These somatic mutations
occur randomly, beginning in prenatal development.20–22 In most
cases, they have no or little phenotypic consequences, as most
mutations have no effect on cellular function or in some cases
are toxic or even lethal to the mutant cell, leading to its quick
disappearance. However, in a few instances, a somatic mutation
confers a competitive advantage to the cell, which leads to the
progressive expansion of the mutant clone. Consequently, indi-

Table. Fifteen Most Frequently Mutated Genes Identified as Candidate Drivers of Clonal Hematopoiesis in Cancer-Free Individuals in Several Human Studies

<table>
<thead>
<tr>
<th>Gene</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNMT3A</td>
<td>31–37,47</td>
</tr>
<tr>
<td>TET2</td>
<td>31,32,34–38,47</td>
</tr>
<tr>
<td>ASXL1</td>
<td>31,32,34–37,47</td>
</tr>
<tr>
<td>JAK2</td>
<td>31–37,47</td>
</tr>
<tr>
<td>TP53</td>
<td>31,32,34–37,47</td>
</tr>
<tr>
<td>PPM1D</td>
<td>31,34,36,47</td>
</tr>
<tr>
<td>IDH2</td>
<td>31–37,47</td>
</tr>
<tr>
<td>CBL</td>
<td>31,32,34–37,47</td>
</tr>
<tr>
<td>SF3B1</td>
<td>31,33–37,47</td>
</tr>
<tr>
<td>SRSF2</td>
<td>31,33,35–37,47</td>
</tr>
<tr>
<td>GNAS</td>
<td>31,34,35,37,47</td>
</tr>
<tr>
<td>KRAS</td>
<td>32,33,35,37,47</td>
</tr>
<tr>
<td>GNB1</td>
<td>31,35,37,47</td>
</tr>
<tr>
<td>NRAS</td>
<td>31–33,35,37</td>
</tr>
<tr>
<td>MYD88</td>
<td>31,35–37</td>
</tr>
</tbody>
</table>

ASXL1 indicates additional sex combs like 1; CBL, Casitas B-lineage lymphoma; DNMT3A, DNA methyltransferase 3α; GNAS, guanine nucleotide-
Clonal hematopoiesis is often driven by a single mutation
in a cancer-related gene, and, accordingly, it is associated with
increased risk of hematologic malignancies.35,36 Despite this,
epidemiological studies show that most individuals carrying
cancer-related somatic mutations that drive clonal expansion
of the mutant cell will never develop blood cancer because this is a rare condition requiring the accumulation of mul-
tiple additional oncogenic gene mutations (Figure [B]).35 On
the basis of these observations, this phenomenon is frequently
referred to hematologists as clonal hematopoiesis of indeter-
minate potential (CHIP).31,32 Although large chromosomal re-
arrangements31,32 and point mutations in >100 cancer-related
genes31,35–37 have been identified as potential drivers of clonal
hematopoiesis, most somatic mutations linked to this phenom-

Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASXL1</td>
<td>additional sex combs like 1</td>
</tr>
<tr>
<td>BM</td>
<td>bone marrow</td>
</tr>
<tr>
<td>CHD</td>
<td>coronary heart disease</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>DNA methyltransferase 3 α</td>
</tr>
<tr>
<td>HSPC</td>
<td>hematopoietic stem/progenitor cell</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>interferon-γ</td>
</tr>
<tr>
<td>IL-1β</td>
<td>interleukin-1β</td>
</tr>
<tr>
<td>JAK2</td>
<td>Janus kinase 2</td>
</tr>
<tr>
<td>TET2</td>
<td>tet methylcytosine dioxygenase 2</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein p53</td>
</tr>
<tr>
<td>GNAS</td>
<td>guanine nucleotide-binding protein, alpha stimulating</td>
</tr>
<tr>
<td>IDH2</td>
<td>protein phosphatase 1D magnesium-dependent, delta isoform</td>
</tr>
<tr>
<td>CBL</td>
<td>Casitas B-lineage lymphoma</td>
</tr>
<tr>
<td>SF3B1</td>
<td>serine- and arginine-rich splicing factor 2</td>
</tr>
<tr>
<td>SRSF2</td>
<td>t(12;21) (q13;q22) tetratricopeptide repeat-containing protein A</td>
</tr>
<tr>
<td>GNAS</td>
<td>guanine nucleotide-binding protein (G protein)</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>GNB1</td>
<td>guanine nucleotide-binding protein (G protein)</td>
</tr>
<tr>
<td>NRAS</td>
<td>neuroblastoma ras oncogene</td>
</tr>
<tr>
<td>MYD88</td>
<td>protein phosphatase 1D magnesium-dependent, delta isoform</td>
</tr>
<tr>
<td>ASXL1</td>
<td>tel methylcytosine dioxygenase 2</td>
</tr>
<tr>
<td>TET2</td>
<td>t(12;21) (q13;q22) tetratricopeptide repeat-containing protein A</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein p53</td>
</tr>
</tbody>
</table>

524 Circulation Research February 2, 2018
been largely neglected. The scarce investigation of the clinical consequences of this phenomenon is somewhat surprising considering that mutations in HSPCs are likely to affect the function of their progeny—immune cells, red blood cells, and platelets—whose dysfunction is at the center of most age-related chronic disorders. This situation is bound to change as evidence has emerged supporting the concept that age-associated somatic mosaicism in the hematopoietic system and clonal hematopoiesis may have major pathophysiological implications in the setting of CVD and other chronic diseases.

Early evidence of a connection between a specific somatic mutation in the hematopoietic system and the development of CVD in the absence of cancer can be found in some small studies that reported the presence of the Janus kinase 2 (JAK2) V617F mutation in blood cells of a higher than expected proportion of cancer-free patients with venous thrombosis,56,57 stable coronary heart disease (CHD),58 or peripheral artery disease.59 Although limited by their small sample size and retrospective nature, these studies, among others, opened the door to the possibility of a connection between somatic mutations in blood cells and CVD. This possibility was reinforced when whole-exome sequencing of blood cells of >5000 cancer-free individuals in 7 independent cohorts revealed that the presence of single-nucleotide variants and small insertions or deletions in any of 160 analyzed hematopoiesis-related genes is associated with an ≈40% increase in all-cause mortality.35 Although the presence of 1 somatic mutation in any of these genes was associated with a ≈40% increase in all-cause mortality, unexpectedly, the increased mortality was associated with a substantial increase in deaths caused by myocardial infarction or stroke among individuals exhibiting a relative frequency of the mutant allele (variant allele fraction) >10%, typically indicative of the presence of >20% blood cells carrying the mutation in heterozygosis. Consistent with this finding, a significant association was found between the detection of somatic mutations in blood cells and the future incidence of atherosclerotic conditions (CHD and stroke): ≈45% of mutation carriers developed atherosclerotic CVD during the study, compared with ≈20% of noncarriers. Thus, carrying somatic mutations in hematopoiesis-related genes increased >2-fold the risk of developing atherosclerotic CVD, an effect that was comparable or even greater than that of various conventional risk factors.35 Although this study reported an association between CVD and a somatic mutation in any of 160 genes, mutations in just 4 genes, namely DNMT3A, TET2, ASXL1, and JAK2, accounted for >70% of the detected mutations. A more recent study has confirmed the existence of independent associations between CHD and mutations in each of these 4 genes with median variant allele fraction ranging from 10% to 20%.47 However, it is likely that larger studies with longer follow-up periods will identify additional mutated genes linked to CHD and that significant associations will be observed even with lower variant allele fraction values. Indeed, this latter study also reported an association between CHD and any of 56 different somatic mutations in less frequently mutated genes, supporting the possibility that other mutated genes may be connected to age-related CVD. Somatic mutations may also be linked to the premature development of CVD in young and middle-aged individuals, as a retrospective case–control analysis of individuals <50 years old revealed a
remarkable 4-fold higher risk of early-onset myocardial infarction in individuals exhibiting somatic mutation-driven clonal hematopoiesis. Furthermore, the presence of somatic mutations in blood cells was also found to be associated with a 3-fold higher risk of exhibiting a high degree of coronary artery calcification, a marker of subclinical atherosclerosis burden. Remarkably, the increased risk of coronary artery calcification was 12-fold in individuals exhibiting a variant allele fraction >10%. 

Overall, these human data suggest a strong and unexpected connection between age-related somatic mutations in hematopoietic cells, clonal hematopoiesis, and atherosclerosis. However, it must be noted that the descriptive nature of these types of epidemiological studies does not allow cause–effect relationships to be established. The associations between somatic mutation-driven clonal hematopoiesis and atherosclerotic CVD could simply reflect shared consequences of the aging process or be secondary to confounding factors. Furthermore, these studies do not fully address the issue of directionality, that is, is clonal hematopoiesis a driver of CVD or are low-grade chronic inflammation and metabolic dysfunction, frequent in subjects at high cardiovascular risk, driving somatic mutagenesis or clonal hematopoiesis as suggested by some researchers. Answering these questions requires the combination of additional human data and carefully designed experimental studies in animal models.

**Somatic Mutations in the Hematopoietic System and Atherosclerotic CVD: Evidence From Mouse Studies, the Case of TET2**

As described above, most reported somatic mutations associated with clonal hematopoiesis and CVD occur in a small number of genes, particularly in 4 genes (DNMT3A, TET2, ASXL1, and JAK2), which are known to modulate hematopoiesis, but whose role in CVD remained mostly unexplored until recently. The first of these genes reported to exhibit somatic mutations in blood cells in individuals with clonal hematopoiesis without blood cancer was TET2. More than 130 different mutations have been reported in this gene in blood cells of cancer-free individuals, which are considered to result in loss of gene function given that most are small insertions/deletions, nonsense mutations, or missense mutations leading to the substitution of key amino acids in the catalytic domain. TET2 is a multifaceted transcriptional regulator that can facilitate both transcriptional activation and repression depending on the molecular/cellular context. It is able to catalyze the conversion of 5-methylcytosine into 5-hydroxymethylcytosine, a process that facilitates DNA demethylation and transcriptional activation. Conversely, TET2 can also mediate transcriptional repression by recruiting histone deacetylases to gene promoters. 

Mouse studies have shown that TET2 deletion or haploinsufficiency results in increased HSPC self-renewal and a bias toward differentiation into the myeloid lineage, consistent with human data linking TET2 mutations with clonal hematopoiesis. However, despite the broad expression pattern of TET2, the relevance of this protein in pathophysiological settings other than stem cell biology or cancer has just recently begun to be explored. In this regard, a recent study from our group demonstrated that TET2 loss-of-function–driven clonal hematopoiesis accelerates atherosclerosis in hyperlipidemic mice, providing experimental evidence in support of the causal contribution of somatic mutation-driven clonal hematopoiesis to atherosclerotic CVD. In this study, experimental conditions in mice recapitulated many features of clonal hematopoiesis linked to somatic TET2 mutations in humans. Competitive bone marrow (BM) transplantation experiments were used to introduce a small number of TET2-deficient cells in atherosclerosis-prone Ldlr−/− mice and mimic the scenario of clonal hematopoiesis, where the mutation is initially present in a small clone that expands over time. In agreement with previous studies, TET2-deficient cells expanded progressively in BM, spleen, and blood in this experimental setting, and they showed a mild myeloid bias, with a preferential expansion into the Ly-6C-high classical monocyte population. Importantly, this did not affect total numbers of white blood cells or their distribution in different subsets, consistent with human studies on cancer-free individuals carrying TET2 mutations. The expansion of TET2−/− cells in these conditions accelerated atherosclerosis substantially, leading to the formation of ≈60% larger plaques. A similar, albeit milder, effect was observed in equivalent transplantation experiments with TET2+− cells, which may mimic better the human scenario given that somatic TET2 mutations are likely to be in heterozygosis in most individuals. In addition, atherosclerotic plaque size was also increased when TET2 ablation was restricted to myeloid cells. These findings were recently validated in independent studies in mice exhibiting full hematopoietic ablation of TET2. Collectively, these experimental studies provide strong support to the existence of a causal connection between somatic mutations in this gene and the development of atherosclerotic CVD.

From a mechanistic point of view, in vitro and in vivo studies suggest that accelerated atherosclerosis in conditions of TET2 loss-of-function–driven clonal hematopoiesis is mainly because of the exacerbated expression of proinflammatory cytokines and chemokines in TET2-deficient macrophages, particularly because of the overproduction of the proinflammatory cytokine IL-1β (interleukin-1β). Interestingly, this mechanism is consistent with the possibility that a small number of TET2-mutant cells in the plaque may be sufficient to drive exacerbated vascular inflammation and atherosclerosis by promoting proinflammatory changes in both mutant and wild-type cells. In this regard, it was found that exacerbated IL-1β production by TET2-deficient plaque cells in mice promotes P-selectin expression and endothelial cell activation in the plaque, leading to increased monocyte recruitment regardless of the TET2 genotype of recruited monocytes. Furthermore, IL-1β has been reported to stimulate its own expression by an autoregulatory feedback loop, and therefore, it is likely that overproduction of IL-1β by TET2-deficient plaque cells promotes further expression of IL-1β in both TET2-deficient and wild-type cells. Hence, it can be speculated that a few TET2-mutant cells in the plaque act in a catalytic manner, amplifying and perpetuating vascular inflammation and atherosclerosis. Consistent with this few bad apples spoil the barrel scenario,
the progressive expansion of Tet2−/− cells in a competitive BM transplantation setting seems to have a comparable effect on atherosclerosis than that of the full ablation of TET2 in all BM cells.47,70 This relatively surprising finding likely reflects the complexity of the actions of TET2 in the hematopoietic system, and it suggests that the effects of TET2 deficiency on atherosclerosis may be dependent on cell type and stage of plaque development. It also provides valuable information on the variety of research strategies available to model clonal hematopoiesis in mice. Although conventional full BM transplantation strategies are the most straightforward strategy to study the effects on atherosclerosis of clonal hematopoiesis-related mutations, the use of cell-type–specific approaches or competitive BM transplantation strategies with low percentages of mutant cells may be advantageous in some instances. This may be the case when the mutant HSPCs exhibit a clear bias to differentiate into specific lineages or when the ubiquitous expression of the mutated gene in hematopoietic progenitors leads to hematologic abnormalities or malignancies not present in most cancer-free individuals exhibiting clonal hematopoiesis (eg, JAK2 gain-of-function mutations61–63).

The use of mouse studies tailored to the human scenario of clonal hematopoiesis may provide clinically relevant information. For instance, the findings in our mouse model of TET2 mutation-mediated clonal hematopoiesis suggest that IL-1β blockade may be particularly effective for the prevention/treatment of CVD in individuals carrying somatic mutations in TET2. Supporting this possibility, pharmacological blockade of NLRP3 (NLR family pyrin domain-containing 3) inflammasome-mediated IL-1β secretion had greater atheroprotective effects in conditions of TET2 loss of function than in wild-type controls and completely suppressed differences in atherosclerosis development between genotypes.70 These findings are especially relevant in the context of the results of the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study), which demonstrated the efficacy of a neutralizing antibody against IL-1β (Canakinumab) in the secondary prevention of atherosclerotic CVD in high-risk patients exhibiting evidence of systemic inflammation.77 Even though Canakinumab has shown efficacy against atherosclerotic CVD, its clinical use poses substantive challenges in the setting of chronic disorders, as it also increases the risk of infections.77 Therefore, this drug, and probably any anti-inflammatory drug, should probably be administered exclusively to those patients who are predicted to show the greatest response to this therapy and to obtain the most atheroprotection from it. Currently, the analysis of hsCRP (high-sensitivity C-reactive protein), a marker of systemic inflammation, is the best available tool to identify these patients and distinguish between responders and nonresponders to anti-inflammatory therapies.79 Although no conclusive data have yet been provided, it can be speculated that clonal hematopoiesis driven by TET2 loss of function or other preleukemic mutations may be associated with increased systemic inflammation in some individuals and that the genetic analysis of blood cells may be used in the future to identify responders to anti-inflammatory therapies in the context of precision medicine strategies.79 In this regard, our preclinical data suggest that individuals with TET2 mutations may respond more favorably than the general population to IL-1β/NLRP3-targeted therapies, thus creating the basis for a personalized therapy for the prevention of accelerated atherosclerotic CVD in individuals carrying somatic mutations in this gene. This notion could be clinically validated through a genetic screening for somatic TET2 mutations in the CANTOS cohort. Furthermore, given that IL-1β plays a pivotal role in vascular inflammation80 and TET2 also affects the expression of other immunomodulatory molecules,77,70,71 it may be of interest to apply similar strategies in ongoing clinical trials with other broad-spectrum anti-inflammatory compounds such as methotrexate81 or colchicine.82

**Somatic Mutation-Driven Clonal Hematopoiesis and Atherosclerotic CVD Beyond TET2: Other Genes and Mechanisms?**

*TET2* was the first gene reported to carry somatic mutations in cancer-free individuals exhibiting clonal hematopoiesis,35 and mutations in this gene have been the first to be causally linked to an age-associated disorder other than cancer, atherosclerotic CVD.35,47,70 However, human evidence suggests that many other mutated genes may contribute to this condition.35,47 As discussed above, independent associations with atherosclerotic CVD have been reported for 3 additional genes, *DNMT3A*, *ASXL1*, and *JAK2*, and mutations in other less frequently mutated genes also seem to be associated with increased risk of atherosclerotic CVD.35,47 It is reasonable to speculate that these additional mutated genes will differentially affect CVD because of their unique functions and mechanisms of action. Some mutations may induce qualitative changes in key immune cells, whereas others may affect the differentiation of HSPCs to specific lineages, leading to quantitative changes in specific immune cell subsets, particularly in individuals who exhibit large mutant clones and a reduced HSPC repertoire. Whether somatic mutations in clonal hematopoiesis-related genes other than TET2 contribute to atherosclerosis remains unexplored, and additional experimental studies are warranted. However, previous research allows for some speculation on the different mechanisms by which some of these mutated genes may promote CVD.

Accumulating experimental evidence suggests that *DNMT3A*, the most frequently mutated gene in cancer-free individuals who exhibit clonal hematopoiesis, is an important modulator of both hematopoiesis and inflammatory responses. This gene encodes for a methyl transferase enzyme that catalyzes DNA methylation and modulates gene transcription in multiple scenarios. Supporting a major role of DNMT3A mutations in clonal hematopoiesis in humans, mouse HSPCs exhibiting heterozygotic DNMT3A loss of function develop a competitive advantage and myeloid skewing over time.83 Importantly, DNMT3A deficiency has also been reported to lead to several potentially proatherogenic phenotypes in immune cells, including exacerbated proinflammatory activation of mast cells,84 increased IFN (interferon)-γ production by T cells,85–87 and restrained immunosuppressive function in myeloid-derived suppressor cells.88 In contrast, DNMT3A inhibition has also been shown to increase the expression of IL-13 in T cells87 and to limit the production of type I interferons in macrophages,89 which could potentially protect against...
atherosclerosis development. Therefore, given the complexity of the immunomodulatory functions of DNMT3A, carefully designed experimental studies will be required to determine the potential contribution of somatic mutations in this gene to CVD.

Another frequently mutated gene for which previous data support a role in CVD is JAK2, which encodes for an important signaling kinase. Indeed, early evidence linking somatic mutations to CVD was provided by the observation that essential thrombocytopenia and polycythemia vera patients carrying the JAK2 V617F gain-of-function mutation exhibit a higher risk of thrombosis. Increased blood counts of leukocytes, red blood cells, and platelets are potential contributors to the increased cardiovascular risk in these patients. However, additional qualitative changes in blood cells are also likely to play a role, as increased cardiovascular risk has been observed in individuals carrying this mutation and exhibiting clonal hematopoiesis with little or no changes in blood cell counts. Some mouse studies suggest that JAK2 V617F-driven clonal hematopoiesis exhibits a clear myeloid, particularly granulocytic, bias, and thus, it is possible that the effects of this somatic mutation on the cardiovascular system are mediated by phenotypic changes in myeloid cells. Given that findings in various experimental models support a role for JAK2 in the modulation of the proinflammatory activities of macrophages and neutrophils, it will be of interest to evaluate the impact of the JAK2 V617F mutation on CVD in the absence of hematologic malignancies.

Beyond the above-mentioned genes, it must be noted that most other mutated genes associated with clonal hematopoiesis have never been evaluated for their role in CVD in any context. Furthermore, controversy exists on whether some of the observed mutations lead to loss or gain of gene function, as is the case of ASXL1 truncation mutations. On the other hand, it is tempting to speculate that some of the somatic mutations that lead to clonal hematopoiesis may be benign or exhibit protective rather than pathogenic effects on the cardiovascular system. In other words, some types of clonal hematopoiesis may be uncoupled from CVD or other age-associated chronic diseases, and these forms of clonal hematopoiesis might be overrepresented in individuals who exhibit exceptional longevity.

**Somatic Mutation-Driven Clonal Hematopoiesis: Many Open Questions**

*Beyond Atherosclerosis, a Role in Other Age-Related Conditions?*

The link between acquired somatic mutation-driven clonal hematopoiesis and atherosclerosis development is now supported by both clinical and preclinical data. However, the possibility that mutations driving clonal hematopoiesis also modulate other forms of CVD or other age-related chronic conditions remains largely unexplored and deserves attention. Indeed, recent preclinical studies in mouse models suggest that TET2 loss-of-function–driven clonal hematopoiesis may accelerate heart failure, a condition that is common in the elderly. Furthermore, human studies have suggested a potential connection between various forms of somatic mutations in blood cells and type 2 diabetes mellitus, chronic pulmonary disease, or psychiatric conditions. Future experimental studies are warranted to examine the nature of these connections, especially given that many of the known mutations that drive clonal hematopoiesis affect immune cells and pathways that are at the center of many age-related chronic disorders.

**Beyond Mutations, What Else Modulates Clonal Hematopoiesis?**

As indicated above, prior exome sequencing studies have suggested that 10% to 20% of individuals older than 65 years old exhibit somatic mutation-driven clonal hematopoiesis leading to a substantial percentage (eg, 20%) of mutant cells in the blood. However, more recent studies using highly sensitive sequencing techniques that allow the detection of mutations in a smaller fraction of blood cells found that the prevalence of clonal hematopoiesis is probably at least double than that initially reported. Furthermore, the seeds for somatic mutation-driven clonal hematopoiesis may be present even in younger individuals, as one recent study using targeted error-corrected sequencing found that somatic mutations in driver genes (most frequently DNMT3A and TET2) are present in a very small fraction of blood cells (eg, 1/3000) in 95% of individuals between 50 and 60 years of age. Similarly, it has been estimated that almost half of healthy individuals at 50 years of age carry at least 1 HSPC with a randomly generated mutation in tumor protein p53 (TP53), another potential driver of clonal hematopoiesis. Thus, the presence of low levels of hematopoietic cells with somatic mutations may be ubiquitous by middle age, but only a fraction of individuals may advance to a condition where the mutant clone undergoes marked expansion. Overall, these observations suggest the existence of additional factors, perhaps genetic or lifestyle factors, that regulate the clonal expansion of mutant HSPCs. For example, some germ line variants, most notably in the JAK2 and TERT genes, have been associated with increased prevalence of clonal hematopoiesis associated with the JAK2 V617F mutation. Furthermore, smoking has also been found to be associated with clonal hematopoiesis. Additional investigations of the effect of these and other factors on somatic mutation-driven clonal hematopoiesis may lead to a better understanding of the complex molecular mechanisms that regulate the dynamics of this process, which could contribute to the development of therapies to prevent it.

**Somatic Mutations in BM Cells: A New Factor to Consider in the Application of Cell Therapies?**

Numerous adult stem cell therapies are being tested in clinical trials or are offered to the public by commercial entities. These therapies often involve the delivery of autologous or allogeneic BM cells or cells from tissues that contain a substantial fraction of BM-derived cells. In addition, some of these procedures use cells that are selected based on the expression of cell surface markers, such as CD34, that lead to the enrichment in HSPCs. Given the realization that somatic mutations in HSPCs can promote their clonal expansion and alter the function of their cellular progeny, questions can be raised about the long-term safety of some of these adult stem cell procedures. It is theoretically possible that the delivery...
of cell fractions from elderly individuals, who may exhibit clonal hematopoiesis, will nullify the therapeutic effect of the transplanted cells or even contribute to adverse outcomes because of the transplantation of hematopoietic cells that harbor somatic mutations. Furthermore, one cannot rule out the possibility that the adoptive transfer of mutant HSPCs could further accelerate their clonal expansion and contribute to disease processes as the patient ages. Future studies are therefore warranted to evaluate whether it might be appropriate to examine transplanted cell populations for their clonal hematopoiesis status before use.

**Clonal Hematopoiesis Without Known Driver Mutations: What Are We Missing?**

Most research efforts to date in the context of clonal hematopoiesis have been focused on the identification of mutations in blood cancer-related genes previously known to modulate hematopoiesis. However, it is noteworthy that ≈50%, or greater, of cases of clonal hematopoiesis occur without any known driver gene mutation. Although this may be related to technical issues in some cases (eg, sequencing depth or specific blood cell populations being sequenced), these results strongly suggest the existence of additional, still unidentified somatic mutations that can drive clonal hematopoiesis and perhaps contribute to age-related disorders. The analysis of chromosomal rearrangements or mutations in nonprotein coding genes may deserve special attention in this context. Indeed, a significant association between the presence of clonally expanded blood cells carrying acquired large chromosomal rearrangements and the occurrence of vascular complications of diabetes mellitus has been reported. Alternatively, nonmutational mechanisms may also contribute to clonal hematopoiesis. Computer simulations suggest that, at least in some cases, clonal hematopoiesis can arise in the absence of a driver mutation simply because of stochastic neutral drift in the HSPC population. Among other nonmutational mechanisms, it is possible, for instance, that epigenetic alterations and the associated cell-to-cell variability in gene expression lead to the dominance of specific HSPC populations. Similarly, the heterogeneous distribution of extracellular signals in the BM niche could lead to the preferential expansion of some HSPCs because of their local environment. Interestingly, clonal hematopoiesis without candidate driver gene mutations has also been associated with an increase in all-cause mortality, although its potential association with CVD remains unexplored. Be it somatic mutations or nonmutational mechanisms, extensive investigation will be required to identify new drivers of clonal hematopoiesis and understand their clinical relevance.

**Conclusions**

The accumulation of random mutations in the hematopoietic system is an unavoidable consequence of the aging process. Although the pathophysiologic relevance of these acquired somatic mutations has been traditionally restricted to the cancer field, emerging evidence suggests that these mutations are important drivers of CVD and potentially many other age-related disorders. A combination of clinical and preclinical studies will be required to understand the pathogenic effects (or lack of) of the various mutated genes, as well as the molecular mechanisms that govern the expansion of mutant hematopoietic stem cells. This information could eventually lead to the design of personalized therapies or preventive strategies for individuals carrying specific somatic mutations in blood cells.

**Acknowledgments**

The illustration was provided by Shradhna Nayak.

**Sources of Funding**

This work was funded by National Institutes of Health grants HL126141, HL131006, HL132564, and HL138014 to K. Walsh and by American Heart Association Scientist Development Grant 17SDG33400213 to J.J. Fuster.

**Disclosures**

None.

**References**


Circulation Research February 2, 2018


